ArticleThe Journal of clinical investigation2018
TET2 controls chemoresistant slow-cycling cancer cell survival and tumor recurrence.
Isabel Puig et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
71 papers cite itlatest 60 shown
this paperpooled itcites it